Brainstorm Cell Therapeutics (BCLI) Competitors $1.86 -0.01 (-0.53%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BCLI vs. LJPC, CSBR, NUVB, SLN, AURA, CRVS, LRMR, ARCT, VERV, and AQSTShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include La Jolla Pharmaceutical (LJPC), Champions Oncology (CSBR), Nuvation Bio (NUVB), Silence Therapeutics (SLN), Aura Biosciences (AURA), Corvus Pharmaceuticals (CRVS), Larimar Therapeutics (LRMR), Arcturus Therapeutics (ARCT), Verve Therapeutics (VERV), and Aquestive Therapeutics (AQST). These companies are all part of the "medical" sector. Brainstorm Cell Therapeutics vs. La Jolla Pharmaceutical Champions Oncology Nuvation Bio Silence Therapeutics Aura Biosciences Corvus Pharmaceuticals Larimar Therapeutics Arcturus Therapeutics Verve Therapeutics Aquestive Therapeutics La Jolla Pharmaceutical (NASDAQ:LJPC) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Does the media refer more to LJPC or BCLI? In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than La Jolla Pharmaceutical. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for La Jolla Pharmaceutical. Brainstorm Cell Therapeutics' average media sentiment score of 0.19 beat La Jolla Pharmaceutical's score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment La Jolla Pharmaceutical Neutral Brainstorm Cell Therapeutics Neutral Do institutionals and insiders believe in LJPC or BCLI? 97.1% of La Jolla Pharmaceutical shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 36.3% of La Jolla Pharmaceutical shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate LJPC or BCLI? Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,512.90%. Given Brainstorm Cell Therapeutics' higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than La Jolla Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score La Jolla Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABrainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in LJPC or BCLI? La Jolla Pharmaceutical received 190 more outperform votes than Brainstorm Cell Therapeutics when rated by MarketBeat users. Likewise, 73.10% of users gave La Jolla Pharmaceutical an outperform vote while only 61.52% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformLa Jolla PharmaceuticalOutperform Votes48173.10% Underperform Votes17726.90% Brainstorm Cell TherapeuticsOutperform Votes29161.52% Underperform Votes18238.48% Is LJPC or BCLI more profitable? La Jolla Pharmaceutical has a net margin of 8.54% compared to Brainstorm Cell Therapeutics' net margin of 0.00%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat La Jolla Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets La Jolla Pharmaceutical8.54% -5.46% 4.00% Brainstorm Cell Therapeutics N/A N/A -373.68% Which has preferable valuation and earnings, LJPC or BCLI? La Jolla Pharmaceutical has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than La Jolla Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLa Jolla Pharmaceutical$75.72M0.00$19.66M$0.12N/ABrainstorm Cell TherapeuticsN/AN/A-$17.19M-$3.45-0.54 Which has more risk and volatility, LJPC or BCLI? La Jolla Pharmaceutical has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. SummaryLa Jolla Pharmaceutical beats Brainstorm Cell Therapeutics on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.90M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.5411.73114.8115.14Price / SalesN/A397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book-1.554.024.665.02Net Income-$17.19M-$42.25M$119.06M$225.46M7 Day Performance-5.08%8.04%0.80%0.37%1 Month Performance-29.55%8.69%5.65%3.57%1 Year Performance-16.39%32.09%36.75%29.43% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics4.1525 of 5 stars$1.86-0.5%$30.00+1,512.9%-17.3%$9.90MN/A-0.5440LJPCLa Jolla PharmaceuticalN/AN/AN/AN/A$155.11M$75.72M51.8461Analyst ForecastNews CoverageCSBRChampions Oncology3.7668 of 5 stars$4.08-4.5%$6.00+47.2%-26.9%$55.38M$50.15M-15.67143Short Interest ↓Positive NewsGap DownNUVBNuvation Bio3.8174 of 5 stars$2.21-3.9%$6.40+189.6%+98.3%$546.25M$1.44M-1.0560Upcoming EarningsSLNSilence Therapeutics2.7473 of 5 stars$18.08+0.6%$57.20+216.4%+104.2%$541.10M$17.90M-14.82100AURAAura Biosciences3.9407 of 5 stars$10.92-2.8%$23.00+110.6%+13.2%$541.01MN/A-6.1050Short Interest ↓CRVSCorvus Pharmaceuticals1.5974 of 5 stars$8.31+8.2%$10.83+30.4%+671.2%$519.80MN/A-18.4730Upcoming EarningsAnalyst DowngradeShort Interest ↑High Trading VolumeLRMRLarimar Therapeutics2.8618 of 5 stars$8.01+0.6%$20.43+155.0%+169.7%$511.05MN/A-7.1530Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageARCTArcturus Therapeutics2.6045 of 5 stars$18.95-0.3%$71.40+276.8%-4.1%$510.36M$147.03M-7.37180Upcoming EarningsNews CoverageGap UpVERVVerve Therapeutics2.3492 of 5 stars$5.97+4.4%$26.00+335.5%-49.5%$501.27M$20.65M-2.31110Upcoming EarningsAQSTAquestive Therapeutics1.7563 of 5 stars$5.49+0.2%$8.83+60.9%+258.4%$499.80M$58.36M-15.69160Upcoming EarningsNews Coverage Related Companies and Tools Related Companies LJPC Competitors CSBR Competitors NUVB Competitors SLN Competitors AURA Competitors CRVS Competitors LRMR Competitors ARCT Competitors VERV Competitors AQST Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCLI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
